Kidney Disease Pharmacology: Drugs, Biologics, Delivery & Devices

The Joy laboratory specializes in research of drugs, biologics, delivery approaches, and devices in kidney disease. We use a variety of in vitro and in vivo methods to best inform about the pharmacology of drugs in diseases of the kidney. Our understanding of pharmacology in this special population comprised of both adults and pediatrics, has enabled the research and development of novel drugs and devices. This is important given that the rate of new drug and device approvals for kidney disease indications is lagging as compared to other therapeutic areas. We also have experience in conducting in vitro and in vivo studies to assess nephrotoxicity and its prevention.

Melanie Joy PharmD, PhD

Professor Professor, Director of Innovation and Commercialization, Director of Entrepreneurship Education, SPARK/REACH Program

Stacey Tuey, B.S.: PhD Student in Pharmaceutical Sciences
Stacey completed her BS degree in Chemistry from California State Polytechnic University of Pomona. Her research focuses on investigating the effects of vitamin D on drug disposition pathways in the chronic kidney disease population. This translational research includes in vitro approaches to understand underlying mechanism of drug metabolism and transport and applies this to a clinical study. Other emphasis areas include pharmacokinetic and physiologically based pharmacokinetic (PBPK) modelling to understand how these mechanisms affect drug concentrations and responses in humans.
Lauren E. Thompson, BS: PhD Student in Pharmaceutical Sciences
Lauren completed her BS degree in Biochemistry with a minor in Mathematics from Denison University in Ohio. Lauren’s research focuses on cisplatin induced acute kidney injury in cancer patients. She has started work investigating nephroprotectant compounds in a mouse cancer model of cisplatin-induced acute kidney injury. She is additionally leading a clinical trial with the goals of elucidating pharmacokinetic and pharmacogenetic determinants that govern renal exposure to cisplatin, as well as the impact of 5-hydroxytryptamine antagonists, a class of anti-emetic drugs. A better understanding of the key processes and pathways involved in renal cisplatin exposure will lead to therapy adjustments to decrease renal exposure and toxicity, while maintaining efficacy.
CMS Login